Lupin Limited has announced the European launch of its biosimilar Ranibizumab, marketed as Ranluspec™. This launch, in partnership with Sandoz, excludes Germany and signifies an important step in broadening access to high-quality biologic treatments for retinal diseases across Europe. The drug is used to treat conditions such as wet age-related macular degeneration and diabetic macular edema.
Lupin Announces European Launch of Biosimilar Ranibizumab
Global pharmaceutical company Lupin Limited has announced the European launch of its biosimilar Ranibizumab, branded as Ranluspec™. This strategic initiative, executed in collaboration with its commercial partner Sandoz, expands the availability of Lupin’s biosimilar treatment across Europe, with the exception of Germany.
Expanding Access to Retinal Treatments
The European launch follows the recent approval of Ranluspec™ by the European Commission in both vial and pre-filled syringe presentations. This milestone is considered a significant stride in enhancing patient access to advanced, high-quality biologic treatment options for a range of serious retinal diseases. Ranibizumab is a crucial therapy for conditions including neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, proliferative diabetic retinopathy, and choroidal neovascularization.
Strategic Importance for Lupin
Thierry Volle, President EMEA and Emerging Markets at Lupin, commented, “The launch of Ranluspec in Europe advances Lupin’s strategy of bringing high-quality biosimilars to more patients suffering from retinal and choroidal vascular diseases. Together with Sandoz, we will expand access to this important treatment across the region.”
Dr. Cyrus Karkaria, President – Biotech Business at Lupin, added, “The launch of Ranluspec reinforces our growing capabilities in biosimilars as it brings together our scientific expertise and manufacturing capabilities in biologics. It underscores our commitment to addressing unmet needs while supporting more sustainable healthcare systems.”
About Lupin Limited
Lupin Limited is a prominent global pharmaceutical leader headquartered in Mumbai, India, with its products distributed in over 100 markets worldwide. The company specializes in a diverse range of pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Lupin holds a strong position in India and the U.S. across multiple therapy areas such as respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health.
Lupin operates 15 state-of-the-art manufacturing facilities and 6 research centers globally, supported by a dedicated workforce of over 26,000 professionals. The company is committed to improving patient health outcomes through its subsidiaries: Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Source: BSE
